On the stock market since 2012, it operates in the world of health and science. It has 3 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 24% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $1.5M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 1,289% — still a thick cushion, though costs have been eating into it lately.
Over the last 12 months, company executives reported 23 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.07. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 3 years, sales fell about 62% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, MITI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MITI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.